arrow_backAll episodes
EP 15
AAV 2.0: Next-Generation Gene Therapy Vectors
This episode explores the revolutionary area of gene therapy, specifically adeno-associated virus (AAV) and its evolution into AAV 2.0. AAV has become a promising tool in drug development, especially with the involvement of artificial intelligence. The discussion delves into the accidental beginnings of AAV, its first big wins, significant barriers, and what's next for AAV 2.0. It highlights how AI is transforming the design and manufacturing of next-generation vectors, addressing previous limitations and opening new possibilities for gene therapy.
Gene TherapyAdeno-Associated Virus (AAV)AAV 2.0Artificial Intelligence (AI)Directed Evolution
Key Concepts
Adeno-Associated Virus (AAV)
- AAV is a small virus that can be engineered to deliver genetic material to cells.
- It has a single-stranded DNA genome and is non-pathogenic in humans.
- AAV can exist in a latent state within cells without causing disease.
Gene Therapy
- Gene therapy involves the use of genes to prevent or treat diseases.
- It can be used to introduce a functional copy of a faulty gene into cells.
- Gene therapy has the potential to treat a wide range of diseases, including rare genetic disorders.
AAV 2.0
- AAV 2.0 refers to the next generation of AAV vectors, engineered to address the limitations of first-generation vectors.
- AAV 2.0 vectors are designed to be more efficient, safer, and more targeted than their predecessors.
- The development of AAV 2.0 involves the use of advanced technologies, including AI and directed evolution.
Artificial Intelligence (AI) in AAV Development
- AI is being used to predict AAV capsid variant performance and identify promising candidates.
- AI can analyze and interpret large datasets, including those generated by next-generation sequencing.
- AI can accelerate the discovery phase of AAV development by identifying the most promising candidates for further testing.
Directed Evolution
- Directed evolution is a technique used to evolve AAV vectors with desired properties.
- It involves the creation of large libraries of AAV variants and the selection of those with the desired traits.
- Directed evolution can be used to improve the efficiency, safety, and targeting of AAV vectors.
Episode Summary
- check_circleThe discovery of AAV in 1965 and its initial characterization as a virus that couldn't replicate efficiently on its own without a helper virus.
- check_circleThe breakthrough in 1978 with the molecular cloning of the AAV genome, enabling the production of AAV particles in the lab.
- check_circleThe optimization of AAV as a vector for gene therapy, leading to its first clinical trials in the 1990s.
- check_circleThe identification of multiple natural AAV serotypes and improvements in laboratory production systems.
- check_circleThe first-generation AAV vectors achieving significant clinical success, including the approval of landmark gene therapies.
- check_circleThe limitations of first-generation AAV vectors, including immunogenicity and manufacturing challenges.
- check_circleThe development of AAV 2.0, involving the creation of engineered vectors from the ground up to address previous limitations.
- check_circleThe use of rational design, directed evolution, and artificial intelligence (AI) in the engineering of AAV 2.0 vectors.
- check_circleAI's role in predicting AAV capsid variant performance, identifying promising candidates, and accelerating the discovery phase.
- check_circleThe application of AI in directed evolution, including the use of machine learning models to analyze and interpret experimental data.
- check_circleThe importance of data and tools, such as protein language models and next-generation sequencing, in supporting AI-driven AAV development.
Full Transcript
Discussion
Join the discussion — sign in to leave a comment.
Log in to comment